retatrutide ly3437943 glp-1 gip glucagon receptor agonist peptide Retatrutide—A Game Changer in Obesity
Description
These shortages will likely continue into the future and will make it hard for patients dealing with Type 2 diabetes and obesity to receive consistent treatment
Adoption has been constrained by affordability, needle aversion and concerns about safety and tolerability
Diabetes Care 46 (Suppl 1), S216S229 (2023)
You can also report suspected side effects directly via the Yellow Card scheme at www.mhra.gov.uk/yellowcard or search for MHRA Yellow Card in the Google Play or Apple App Store
Finally, pricing is a very political issue despite the substantial health benefits and third-party cost-effectiveness data
